Michael Lutz, MD
Urology · Rochester Hills, MINPI 1326020157
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 58.9% of the total. Reporting peaked in 2020 at $7,495 and has fallen 99.6% since, to $33 in 2025.
Across 212 payments — averaging $93.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$12K
- Tolmar Pharmaceuticals, Inc.$4K
- Johnson & Johnson$1K
- Astellas Pharma US Inc$581
- Dendreon Pharmaceuticals LLC$330
- Pfizer$280
- plus $2K from 29 others
What the payments were for
- Consulting fees$2,33512%
- Speaking & faculty fees$10,08551%
- Travel & lodging$2,61513%
- Food & beverage$4,59023%
- Education$1681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 35 | $11,650 |
| Tolmar Pharmaceuticals, Inc. | 12 | $3,701 |
| Johnson & Johnson | 13 | $1,195 |
| Astellas Pharma US Inc | 31 | $581 |
| Dendreon Pharmaceuticals LLC | 13 | $330 |
| Pfizer | 23 | $280 |
| Teleflex LLC | 3 | $185 |
| Myriad Genetic Laboratories, Inc. | 4 | $169 |
| Sun Pharmaceutical Industries Inc. | 8 | $161 |
| Bayer | 7 | $147 |
| Blue Earth Diagnostics | 8 | $130 |
| Medtronic | 5 | $114 |
| Endo Pharmaceuticals Inc. | 2 | $112 |
| Laborie Medical Technologies Corp. | 2 | $106 |
| Merck | 4 | $100 |
| Antares Pharma, Inc. | 5 | $94 |
| Boston Scientific | 3 | $92 |
| AbbVie(2 entities) | 5 | $68 |
| Urogen Pharma, Inc. | 3 | $67 |
| Coloplast | 3 | $51 |
| AstraZeneca | 3 | $48 |
| Clarus Therapeutics Inc. | 2 | $45 |
| Photocure Inc | 2 | $44 |
| Halozyme Inc | 2 | $42 |
| Progenics Pharmaceuticals, Inc. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Janssen Scientific Affairs, LLC | 2 | $33 |
| Procept Biorobotics Corporation | 1 | $26 |
| Sanofi | 1 | $26 |
| Immunitybio, Inc. | 1 | $24 |
| 180 Medical, Inc. | 1 | $24 |
| Zyla Life Sciences, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,794 in reported general payments places this provider in the 85th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 43 | $582,417 |
| MyrbetriqMirabegron | 127 | $116,830 |
| GemtesaVibegron | 17 | $22,271 |
| Tamsulosin Hcl | 618 | $14,086 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 309 | $9,522 |
| Silodosin | 62 | $7,094 |
| Finasteride | 344 | $6,943 |
| Dutasteride | 160 | $6,200 |
| Mirabegron ErMirabegron | 14 | $5,991 |
| Tolterodine Tartrate ErTolterodine Tartrate | 52 | $5,822 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 43 | $1,414 |
| Desmopressin Acetate | 15 | $1,112 |
| Testosterone | 13 | $1,029 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,002 |
| Testosterone Cypionate | 23 | $856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $581 | $699,247170 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $40 | $22,27117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 urology providers in Michigan.
Other urology in Rochester Hills
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Richard BennettRoyal Oak$361K
- Ryan NelsonUtica$296K
- Casey DauwAnn Arbor$188K
- Aram LoebDetroit$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.